Table 3.
Body weight change between baseline and month 1 by statin use
| Statin | Patients (n) | Median (Interquartile Range) | P Value |
|---|---|---|---|
| Placebo | 285 | 0.0 (−1.0 to 1.0) | <0.001 |
| Avosentan | 476 | 0.6 (0.0 to 2.0) | |
| Avosentan+no statin | 225 | 0.0 (−0.1 to 1.0) | <0.001 |
| Avosentan+statin | 251 | 1.0 (0.0 to 2.5) | |
| Avosentan+simvastatin (major)a | 98 | 1.1 (0.0 to 2.4) | |
| Avosentan+lovastatin (major)a | 29 | 1.1 (0.0 to 2.5) | |
| Avosentan+atorvastatin (moderate)a | 105 | 0.8 (0.0 to 2.6) | 0.44 |
| Avosentan+pravastatin (minor)a | 4 | 2.6 (1.1 to 5.1) | |
| Avosentan+rosuvastatin (no)a | 6 | 0.8 (−1.0 to 1.7) | |
| Avosentan+fluvastatin (no)a | 10 | 0.6 (0.0 to 2.0) |
One patient was treated with both simvastatin and lovastatin. Comparison testing with Wilcoxon rank-sum tests for two groups and with one-way ANOVA for more than two groups.
a
Degree of CYP3a4 metabolism as discussed by Williams and Feely (25).